RenovoRx Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

RNXT$1.18+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

(in thousands)

	Years Ended December 31,
2023 · 2022
Cash flows from operating activities:
Net loss	$(10,232)		$(9,889)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,078		644
Amortization on leasehold improvements	-		6
Change in fair value of common stock warrants classified as a liability	(1,709)		-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	633		264
Other assets	(101)		9
Accounts payables	27		-
Accrued expenses	46		155
Net cash used in operating activities	(10,258)		(8,811)
Cash flows from investing activities:
Purchases of marketable securities	-		(8,000)
Proceeds from maturities of marketable securities	-		5,968
Proceeds from the sale of investments	2,032		-
Net cash provided by (used in) investing activities	2,032		(2,032)
Cash flows from financing activities:
Proceeds from common stock and pre-funded common stock warrants	5,000		-
Proceeds from exercise of stock options	8		42
Net cash provided by financing activities	5,008		42
Net decrease in cash and cash equivalents	(3,218)		(10,801)
Cash and cash equivalents:
Beginning of year	4,391		15,192
End of year	$1,173		$4,391
Supplemental of non-cash financing activities:
Fair value of common warrant classified as a liability	$3,291	$	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.